Chris Hart

Scientist, founder, innovator; captivated by the interface of AI, Genomics, modern biology and it's potential for imparting positive impact.

[Creyon Bio @creyonbio]

Our CEO @chrihart is presenting at #MedInvest2024! Discover how we're engineering OBMs 100x more efficiently and learn about our AI-driven platform that's overcoming delivery challenges with targeted aptamers, transforming treatments for diseases.

https://t.co/bbErsoYxto

[Creyon Bio @creyonbio]

We're officially welcoming Shaquille Vayda @Lux_Capital, to Creyon's Board of Directors!

Shaq’s diverse experience spanning technology, aerospace and life sciences aligns well with our innovative approach to drug engineering.

https://t.co/vyGfVl3WWO

[Creyon Bio @creyonbio]

Please welcome Serge Messerlian @DCVC, to our Board of Directors!

With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs.

https://t.co/G2EFkMro3k

[Creyon Bio @creyonbio]

Our CEO @chrihart proposes a paradigm shift in how we approach oligonucleotide-based medicine development, emphasizing the need to understand the complex interplay between sequence and chemistry.

Read more in @NAInsights: https://t.co/BvnGkw4VQK

[Creyon Bio @creyonbio]

Baby Leo’s experience with #raredisease highlights the need for precision treatments.

Grateful for our work with the TNPO2 Foundation. Read more about Leo's journey and how we engineered this particular investigational antisense oligonucleotide therapy. https://t.co/OgaThcOgGC

[Creyon Bio @creyonbio]

We're honored to share about our efforts to quickly develop precision medicines for rare and common diseases, whether for millions of patients or for just one, and to be included among so many other amazing @DCVC and @DCVCBio portfolio companies.

https://t.co/JljNJ4cKTZ

[Chris Hart @chrihart]

Thanks @bios_community for such a good conversation about how @creyonbio is learning the principles to engineer safe and efficacious Oligonucleotide-Based Medicines from idea through the clinic.

[BIOS @bios_community]

Tune into our new BIOS Builders episode as we dive deep into the world of engineering gene-centric medicines🎙️

Our guests: @chrihart and Swag, co-founders of @creyonbio 🧵

See our episode below...

https://t.co/Ogl61FOPdx

[Chris Hart @chrihart]

Grateful to share some of our latest research at @OTSociety. A small glimpse into our efforts at Creyon. Looking forward to sharing more of the brilliant work being done by the exceptional interdisciplinary Creyon team.

[Creyon Bio @creyonbio]

Creyon is excited to be at the @OTSociety annual meeting this week sharing a poster highlighting a novel in vitro assay to measure the acute effects of ASOs on neural activity across time, at single-cell resolution, and at a high-throughput scale. #OTS22 #oligonucleotide

[Chris Hart @chrihart]

Congratulations and thank you to the @CreyonBio teammates who completed this foundational work and shared the results of a novel approach in arXiv: https://t.co/xLLAnynec2.
#oglionucleotide #artificialintelligence #machinelearning

[Creyon Bio @creyonbio]

We are pleased to announce @DavidFajgenbaum, MD, MBA, as a Company Advisor & Board Observer. A leader in research & drug development, he will help Creyon connect with regulatory, patient, & clinical communities. Read more: https://t.co/SswdYfSuqL #PrecisionMedicine #Biotech

[Chris Hart @chrihart]

Join our amazing team @creyonbio. Come do great science, work closely and collaboratively with brilliant minds across multiple disciplines, and work on problems that will have a meaningful impact. Details - https://t.co/POTf0FvGDm

[Chris Hart @chrihart]

Thrilled to announce that David Dimmock has joined us @creyonbio. He joins our amazing interdisciplinary team, grounding and connecting us deeply to the needs of the clinic.

#oligonucleotide #PrecisionMedicine

[Creyon Bio @creyonbio]

We are excited to welcome Dr. David Dimmock as our Chief Medical Officer. His passion and experience will be incredibly valuable as we work together to change how precision medicines are created for patients. Read more: https://t.co/SswdYfSuqL

[Creyon Bio @creyonbio]

We were excited to talk with @cenmag about our work to develop oligonucleotide-based medicines for people living with rare and common diseases. Read more: https://t.co/4gUs6AUgkD #AI #MachineLearning #Biotech

[DCVC Bio @DCVCBio]

.⁦@creyonbio⁩ exits stealth to disrupt RNA drug dev. 2 years ago we backed one of the most exciting projects we have ever been a part of. Custom oligo based medicines, on demand, for diseases from ultra rare to common, via proprietary structural AI. https://t.co/KTv8Jvvq1y

[Chris Hart @chrihart]

@mattocko - thank you!! We couldn’t be more excited to be working with the visionary teams at @DCVC / @DCVCBio and @Lux_Capital supporting our efforts in building a platform to make precision oligonucleotide-based medicines on demand a real possibility.

[Chris Hart @chrihart]

@wolfejosh @creyonbio We couldn't be more thrilled to be part of the Lux family! Amazing to have the support and brilliance of the Lux team on our side.

[Chris Hart @chrihart]

It’s been very hard keeping quiet for the last two years - thank you for your early and continued support in making our bold vision a reality.

[Zavain Dar @zavaindar]

2 years ago we secretly backed one of the most exciting projects I’ve ever been a part of. Custom oligonucleotide based medicines, on demand, for diseases ranging ultra rare to common. After leading a $40M Series A - today we exit stealth: @creyonbio

https://t.co/pd9oLzpjLS

[Creyon Bio @creyonbio]

Today, Creyon Bio launched to develop oligonucleotide-based medicines for people living with common and rare diseases. Our Chief Scientific Officer Swagatam Mukhopadhyay dives deeper into our science. Learn more here: https://t.co/iTOLbKPyib #PrecisionMedicine #Biotech

[Chris Hart @chrihart]

Creyon Bio launched today! Creyon has a bold vision and big dreams. And to make big dreams a reality, you need a great team! Honored to be working with so many exceptional people and groups.

[Creyon Bio @creyonbio]

Today, we launched with the goal to make on demand precision medicines a real possibility for patient populations of all sizes. We are working to design safe, effective oligonucleotide-based medicines for genetic diseases. Learn more here: https://t.co/iTOLbKPyib #Biotech

[Chris Hart @chrihart]

... and it begins.